Mumbai: American biotech firm Moderna on Monday announced its experimental vaccine against COVID-19, which was 94.5 percent effective, the second major success in the vaccine hunt.
US pharmaceutical company Pfizer and its German partner BioNotech said last week that their vaccine was 90 percent effective.
Moderna released early results from a clinical trial with more than 30,000 participants. “This positive interim analysis from a Phase 3 study gave us the first clinical recognition that our vaccine can prevent COVID-19 disease, including critical illness,” said Stephen Bansell, CEO of Moderna.
The company plans to submit an application for emergency approval in the US and around the world within weeks and says it expects to have about 20 million doses ready to ship in the US by the end of the year.
The global infection from COVID-19 has increased from 1.3 million to more than 54 million since the virus emerged at the end of last year in China.
The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and preliminary results are based on 95 volunteers from 30,000 who fell ill with COVID19.
Of the 95, 90 had been in the trial’s placebo group and five in the group that received the drug called mRNA-1273.
(With Agency Inputs)